Anemia in chronic kidney disease patients: treatment recommendations and emerging therapies

References

• Anand IS, Chandrashekhar Y, Ferrari R, et al. Pathogenesis of oedema in chronic severe anaemia: studies of body water and sodium, renal function, haemodynamic variables, and plasma hormones. Br Heart J 1993;70:357-62
   PubMedGoogle Scholar
• Locatelli F, Pisoni RL, Combe C, et al. Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2004;19(1):121-32
   PubMed Web of Science ®Google Scholar
• Volkova N, Arab L. Evidence-based systematic literature review of hemoglobin/hematocrit and all-cause mortality in dialysis patients. Am J Kidney Dis 2006;47(1):24-36
   PubMed Web of Science ®Google Scholar
• Strippoli GF, Navaneethan SD, Craig JC. Haemoglobin and haematocrit targets for the anaemia of chronic kidney disease. Cochrane Database Syst Rev 2006(4):CD003967
   Google Scholar
• Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;335:2085-98
   Web of Science ®Google Scholar
• Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006;335:2071-84
   Web of Science ®Google Scholar
• KDOQI. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease, 2007 update of hemoglobin target. Am J Kidney Dis 2007;50(3):471-530
   PubMed Web of Science ®Google Scholar
• Locatelli F, Del Vecchio L. Haemoglobin levels and health-related quality of life in young and elderly patients on specialized predialysis care. Nephrol Dial Transplant 2014;29(7):1391-8
   PubMedGoogle Scholar
• Pfeffer MA, Burdmann EA, Chen CY, et al. TREAT investigators. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009;361:2019-32
   PubMed Web of Science ®Google Scholar
• Skali H, Parving HH, Parfrey PS, et al. TREAT Investigators. Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience. Circulation 2011;124(25):2903-8
   PubMed Web of Science ®Google Scholar
• Locatelli F, Aljama P, Canaud B, et al. Anaemia Working Group of European Renal Best Practice (ERBP. Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to reduce cardiovascular events with Aranesp therapy (TREAT) study. Nephrol Dial Transplant 2010;25(9):2846-50
   PubMed Web of Science ®Google Scholar
• KDIGO. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int 2012;2(4):279-335
   Google Scholar
• Locatelli F, Bárány P, Covic A, et al. ERA-EDTA ERBP Advisory Board. Kidney Disease: improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. Nephrol Dial Transplant 2013;28(6):1346-59
   PubMed Web of Science ®Google Scholar
• Kliger AS, Foley RN, Goldfarb DS, et al. KDOQI US commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD. Am J Kidney Dis 2013;62(5):849-59
   PubMed Web of Science ®Google Scholar
• Moist LM, Troyanov S, White CT, et al. Canadian Society of Nephrology commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD. Am J Kidney Dis 2013;62(5):860-73
   PubMed Web of Science ®Google Scholar
• Stancu S, Barsan L, Stanciu A, Mircescu G. Can the response to iron therapy be predicted in anemic nondialysis patients with chronic kidney disease? Clin J Am Soc Nephrol 2010;5:409-16
   PubMed Web of Science ®Google Scholar
• Stancu S, Stanciu A, Zugravu A, et al. Bone marrow iron, iron indices, and the response to intravenous iron in patients with non-dialysis-dependent CKD. Am J Kidney Dis 2010;55(4):639-47
   PubMed Web of Science ®Google Scholar
• Coyne DW, Kapoian T, Suki W, et al. DRIVE Study Group. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients’ Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol 2007;18(3):975-84
   PubMed Web of Science ®Google Scholar
• Kapoian T, O’Mara NB, Singh AK, et al. Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol 2008;19(2):372-9
   PubMedGoogle Scholar
• Rostoker G, Griuncelli M, Loridon C, et al. Hemodialysis-associated Hemosiderosis in the Era of Erythropoiesis-stimulating Agents: a MRI Study. Am J Med 2012;125(10):991-9
   PubMed Web of Science ®Google Scholar
• Susantitaphong P, Alqahtani F, Jaber BL. Efficacy and safety of intravenous iron therapy for functional iron deficiency anemia in hemodialysis patients: a meta-analysis. Am J Nephrol 2014;39(2):130-41
   PubMed Web of Science ®Google Scholar
• Martin-Malo A, Merino A, Carracedo J, et al. Effects of intravenous iron on mononuclear cells during the haemodialysis session. Nephrol Dial Transplant 2012;27(6):2465-71
   PubMed Web of Science ®Google Scholar
• Kumbasar A, Gursu M, Kaya C, et al. The effect of different doses and types of intravenous iron on oxidative stress and inflammation in hemodialysis patients. J Nephrol 2012;25(5):825-32
   PubMed Web of Science ®Google Scholar
• De Nicola L, Locatelli F, Conte G, Minutolo R. Responsiveness to erythropoiesis-stimulating agents in chronic kidney disease: does geography matter? Drugs 2014;74(2):159-68
   PubMedGoogle Scholar
• Del Vecchio L, Pozzoni P, Andrulli S, Locatelli F. Inflammation and resistance to treatment with recombinant human erythropoietin. J Ren Nutr 2005;15(1):137-41
   PubMedGoogle Scholar
• Kalantar-Zadeh K, Lee GH, Miller JE, et al. Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients. Am J Kidney Dis 2009;53(5):823-34
   PubMed Web of Science ®Google Scholar
• Streja E, Kovesdy CP, Greenland S, et al. Erythropoietin, iron depletion, and relative thrombocytosis: a possible explanation for hemoglobin-survival paradox in hemodialysis. Am J Kidney Dis 2008;52(4):727-36
   PubMed Web of Science ®Google Scholar
• Szczech LA, Barnhart HX, Inrig JK, et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int 2008;74(6):791-8
   PubMed Web of Science ®Google Scholar
• Nishio A, Chhatkuli BP, Ma JZ, Kalantari K. Higher doses of erythropoietin-stimulating agents and hyporesponsiveness to their effects are associated with increased mortality among prevalent hemodialysis patients. Blood Purif 2013;36(1):29-36
   PubMedGoogle Scholar
• Zhang Y, Thamer M, Stefanik K, et al. Epoetin requirements predict mortality in hemodialysis patients. Am J Kidney Dis 2004;44(5):866-76
   PubMed Web of Science ®Google Scholar
• McCullough PA, Barnhart HX, Inrig JK, et al. Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease. Am J Nephrol 2013;37(6):549-58
   PubMed Web of Science ®Google Scholar
• Solomon SD, Uno H, Lewis EF, et al. Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) Investigators. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med 2010;363(12):1146-55
   PubMed Web of Science ®Google Scholar
• Bailie GR, Schuler C, Leggett RE, et al. Oxidative effect of several intravenous iron complexes in the rat. Biometals 2013;26(3):473-8
   PubMedGoogle Scholar
• Lyseng-Williamson KA, Keating GM. Ferric carboxymaltose: a review of its use in iron-deficiency anaemia. Drugs 2009;69(6):739-56
   PubMedGoogle Scholar
• Covic A, Mircescu G. The safety and efficacy of intravenous ferric carboxymaltose in anaemic patients undergoing haemodialysis: a multi-centre, open-label, clinical study. Nephrol Dial Transplant 2010;25(8):2722-30
   PubMedGoogle Scholar
• Grimmelt AC, Cohen CD, Fehr T, et al. Safety and tolerability of ferric carboxymaltose (FCM) for treatment of iron deficiency in patients with chronic kidney disease and in kidney transplant recipients. Clin Nephrol 2009;71(2):125-9
   PubMedGoogle Scholar
• Onken JE, Bregman DB, Harrington RA, et al. Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial. Nephrol Dial Transplant 2013. [Epub ahead of print]
   PubMedGoogle Scholar
• Wolf M, Koch TA, Bregman DB. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J Bone Miner Res 2013;28(8):1793-803
   PubMed Web of Science ®Google Scholar
• Spinowitz BS, Kausz AT, Baptista J, et al. Ferumoxytol for treating iron deficiency anemia in CKD. J Am Soc Nephrol 2008;19(8):1599-605
   PubMed Web of Science ®Google Scholar
• Provenzano R, Schiller B, Rao M, et al. Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients. Clin J Am Soc Nephrol 2009;4(2):386-93
   PubMed Web of Science ®Google Scholar
• Singh A, Patel T, Hertel J, et al. Safety of ferumoxytol in patients with anemia and CKD. Am J Kidney Dis 2008;52(5):907-15
   PubMed Web of Science ®Google Scholar
• Macdougall IC, Strauss WE, McLaughlin J, et al. A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD. Clin J Am Soc Nephrol 2014. [Epub ahead of print]
   PubMedGoogle Scholar
• Wikstrom B, Bhandari S, Barany P, et al. Monofer, a novel intravenous iron oligosaccharide for treatment of iron deficiency in patients with chronic kidney disease (CKD). Poster No.M560 World Congress of Nephrology; Milan, Italy; 22-26 May 2009
   Google Scholar
• Franchini M, Montagnana M, Lippi G. Hepcidin and iron metabolism: from laboratory to clinical implications. Clin Chim Acta 2010;411(21-22):1565-9
   PubMedGoogle Scholar
• Visciano B, Nazzaro P, Tarantino G, et al. Liposomial iron: a new proposal for the treatment of anaemia in chronic kidney disease. G Ital Nefrol 2013;30:5
   Google Scholar
• Seligman PA, Moore GM, Schleicher RB. Clinical studies of HIP: an oral heme-iron product. Nutr Res 2000;20:1279-86
   Google Scholar
• Barraclough KA, Brown F, Hawley CM, et al. A randomized controlled trial of oral heme iron polypeptide versus oral iron supplementation for the treatment of anaemia in peritoneal dialysis patients: HEMATOCRIT trial. Nephrol Dial Transplant 2012;27(11):4146-53
   PubMedGoogle Scholar
• Nagaraju SP, Cohn A, Akbari A, et al. Heme iron polypeptide for the treatment of iron deficiency anemia in non-dialysis chronic kidney disease patients: a randomized controlled trial. BMC Nephrol 2013;14:64
   PubMedGoogle Scholar
• Yokoyama K, Hirakata H, Akiba T, et al. Effect of oral JTT-751 (ferric citrate) on hyperphosphatemia in hemodialysis patients: results of a randomized, double-blind, placebo-controlled trial. Am J Nephrol 2012;36(5):478-87
   PubMed Web of Science ®Google Scholar
• Wüthrich RP, Chonchol M, Covic A, et al. Randomized clinical trial of the iron-based phosphate binder PA21 in hemodialysis patients. Clin J Am Soc Nephrol 2013;8(2):280-9
   PubMed Web of Science ®Google Scholar
• Phan O, Maillard M, Peregaux C, et al. PA21, a new iron-based noncalcium phosphate binder, prevents vascular calcification in chronic renal failure rats. J Pharmacol Exp Ther 2013;346(2):281-9
   PubMed Web of Science ®Google Scholar
• Iida A, Kemmochi Y, Kakimoto K, et al. Ferric citrate hydrate, a new phosphate binder, prevents the complications of secondary hyperparathyroidism and vascular calcification. Am J Nephrol 2013;37(4):346-58
   PubMed Web of Science ®Google Scholar
• Maguer-Satta V, Bartholin L, Jeanpierre S, et al. Regulation of human erythropoiesis by activin A, BMP2, and BMP4, members of the TGFbeta family. Exp Cell Res 2003;282:110-20
   PubMed Web of Science ®Google Scholar
• Lotinun S, Pearsall RS, Davies MV, et al. A soluble activin receptor Type IIA fusion protein (ACE-011) increases bone mass via a dual anabolic-antiresorptive effect in Cynomolgus monkeys. Bone 2010;46:1082-8
   PubMed Web of Science ®Google Scholar
• Majmundar AJ, Wong WJ, Simon MC. Hypoxia-inducible factors and the response to hypoxic stress. Mol Cell 2010;40(2):294-309
   PubMed Web of Science ®Google Scholar
• Besarab A, Hulter HN, Klaus S, et al. FG-4592, a Novel Oral HIF Prolyl Hydroxylase Inhibitor, Elevates Hemoglobin in Anemic Stage 3/4 CKD Patients. American Society of nephrology Renal Week 2010; Denver (CO), USA; November 16-21. Abstract [SA-FC416]
   Google Scholar
• Provenzano R, et al. Evaluation of FG-4592, a novel oral hypoxia-inducible factor prolyl hydroxylase inhibitor, to treat anemia in hemodialysis patients. National Kidney Foundation Conference 2011; Abstract #188
   Google Scholar
• Besarab A, Chernyavskaya EN, Motylev I, et al. FG-4592, an oral hypoxia-inducible factor propyl hydroxylase inhibitor, corrects anemia without iron supplementation in incident dialysis patients. J Am Soc Nephrol 2012;23:21A; Abstract
   Google Scholar
• Besarab A, Tak Mao Chan D, Dua SL, et al. Hypoxia inducing factor propyl hydroxylase inhibitor FG-4592 corrects anemia in peritoneal dialysis. J Am Soc Nephrol 2013;24:91A; Abstract
   Google Scholar
• Boettcher MF, Lentini S, Kaiser A, et al. First-in-man study with BAY 85-3934 – a new oral selective HIF-PH inhibitor for the treatment of oral anemia. J Am Soc Nephrol 2013;24:347a; Abstract
   Google Scholar
• Ganz T, Nemeth E. Hepcidin and disorders of iron metabolism. Annu Rev Med 2011;62:347-60
   PubMed Web of Science ®Google Scholar
• Fuller DS, Pisoni RL, Bieber BA, et al. The DOPPS practice monitor for U.S. dialysis care: update on trends in anemia management 2 years into the bundle. Am J Kidney Dis 2013;62(6):1213-16
   PubMedGoogle Scholar
• Canavese C, Bergamo D, Ciccone G, et al. Validation of serum ferritin values by magnetic susceptometry in predicting iron overload in dialysis patients. Kidney Int 2004;65(3):1091-8
   PubMed Web of Science ®Google Scholar
• Dimova I, Popivanov G, Djonov V. Angiogenesis in cancer - general pathways and their therapeutic implications. J Buon 2014;19(1):15-21
   PubMed Web of Science ®Google Scholar
• Boyer DS, Hopkins JJ, Sorof J, Ehrlich JS. Anti-vascular endothelial growth factor therapy for diabetic macular edema. Ther Adv Endocrinol Metab 2013;4(6):151-69
   PubMedGoogle Scholar
• Akebia Meets Primary Endpoint in Phase 2 Study of Once-Daily, Oral Anemia Treatment, AKB-6548. Available from: www.businesswire.com/news/home/20120405005347/en/Akebia-Meets-Primary-Endpoint-Phase-2-Study [Last accessed 15 October 2013]
   Google Scholar
• Bennett L. Patient independence in chronic kidney disease and anaemia: implications of the 2012 KDIGO guideline. J Ren Care 2013;39(2):108-17
   PubMedGoogle Scholar
• Fuller DS, Pisoni RL, Bieber BA, et al. The DOPPS practice monitor for U.S. dialysis care: update on trends in anemia management 2 years into the bundle. Am J Kidney Dis 2013;62(6):1213-16
   PubMedGoogle Scholar
• Haag-Weber M, Eckardt KU, Hörl WH, et al. Safety, immunogenicity and efficacy of subcutaneous biosimilar epoetin-α (HX575) in non-dialysis patients with renal anemia: a multi-center, randomized, double-blind study. Clin Nephrol 2012;77(1):8-17
   PubMed Web of Science ®Google Scholar
• Locatelli F, Del Vecchio L. Peginesatide as a new approach for treating anemia of CKD patient: is it like a falling star? Expert Opin Pharmacother 2013;14(10):1277-80
   PubMed Web of Science ®Google Scholar
• European medicines agency. Available from: www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/06/news_detail_001833.jsp&mid=WC0b01ac058004d5c1 [Last accessed 26 February 2014]
   Google Scholar
• FDA. Available from: www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm340895.htm [Last accessed 31 March 2014]
   Google Scholar
• Clinical trials. Available from: http://clinicaltrials.gov/ct2/results?term=AKB-6548+&Search=Search [Last accessed 31 March 2014]
   Google Scholar
• Akebia Meets Primary Endpoint in Phase 2 Study of Once-Daily, Oral Anemia Treatment, AKB-6548. Available at www.businesswire.com/news/home/20120405005347/en/Akebia-Meets-Primary-Endpoint-Phase-2-Study [Last accessed 31 March 2014]
   Google Scholar
• GSK. Available at www.gsk-clinicalstudyregister.com/result_comp_list.jsp?compound=GSK1278863 [Last accessed 31 March 2014]
   Google Scholar